AnaptysBio, Inc. (ANAB)
45.95
-0.26
(-0.56%)
USD |
NASDAQ |
Oct 09, 16:00
46.00
+0.05
(+0.11%)
After-Hours: 20:00
AnaptysBio Debt to Equity Ratio : 25.47 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 25.47 |
| March 31, 2026 | 21.76 |
| December 31, 2025 | 7.811 |
| September 30, 2025 | -11.78 |
| June 30, 2025 | -7.745 |
| March 31, 2025 | 10.17 |
| December 31, 2024 | 5.213 |
| September 30, 2024 | 4.351 |
| June 30, 2024 | 38.36 |
| March 31, 2024 | 6.856 |
| December 31, 2023 | 3.73 |
| September 30, 2023 | 2.737 |
| June 30, 2023 | 2.214 |
| March 31, 2023 | 1.709 |
| December 31, 2022 | 1.236 |
| September 30, 2022 | 1.158 |
| June 30, 2022 | 0.9242 |
| March 31, 2022 | 0.835 |
| December 31, 2021 | 0.0588 |
| September 30, 2021 | 0.0546 |
| June 30, 2021 | 0.0539 |
| March 31, 2021 | 0.0005 |
| December 31, 2020 | 0.0009 |
| September 30, 2020 | 0.0025 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.0029 |
| March 31, 2020 | 0.0033 |
| December 31, 2019 | 0.0072 |
| September 30, 2019 | 0.0114 |
| June 30, 2019 | 0.015 |
| March 31, 2019 | 0.0184 |
| December 31, 2018 | 0.0169 |
| September 30, 2018 | 0.0198 |
| June 30, 2018 | 0.0408 |
| March 31, 2018 | 0.0453 |
| December 31, 2017 | 0.0469 |
| September 30, 2017 | 0.1408 |
| June 30, 2017 | 0.1293 |
| March 31, 2017 | 0.1268 |
| December 31, 2016 | 0.3517 |
| September 30, 2016 | 0.1144 |
| June 30, 2016 | 0.1116 |
| March 31, 2016 | 0.1179 |
| December 31, 2015 | 0.1158 |
| September 30, 2015 | 0.107 |
| June 30, 2015 | 0.8283 |
| March 31, 2015 | 0.8441 |
| December 31, 2014 | 0.7998 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
| Imunon, Inc. | 1.873 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 346.01M |
| Total Liabilities (Quarterly) | 335.42M |
| Shareholders Equity (Quarterly) | 10.58M |
| Current Ratio | 5.613 |
| Net Debt Paydown Yield | 0.76% |